Vice President, Finance
Christopher M. Lindblom joined Cedilla Therapeutics as Vice President, Finance in July 2021. Chris’ 19-year biotech career spans both public and private biotech companies from driving long-range financial plans in concert with strategic planning to playing a key role in helping biotech companies raise capital, from confidential follow-on offerings for public companies to private equity rounds and venture debt deals. He is also experienced in executing mergers and acquisitions, as well as ensuring productive R&D and commercial collaborations. His other key responsibilities have included budgeting and forecasting, accounting and financial reporting (including for the SEC), tax planning and compliance, treasury and corporate insurance.
Prior to joining Cedilla Therapeutics, Chris served as Vice President, Finance at IFM Therapeutics, Cogen Immune Medicine (up through its merger with Torque Therapeutics to form Repertoire Immune Medicines) and Warp Drive Bio (up through its acquisition by Revolution Medicines). Chris held various senior finance roles for the first 11+ years in biotech at Millennium Pharmaceuticals, including the commercial launch of VELCADE®, and at Infinity Pharmaceuticals. Chris also served as Vice President of Finance at Ovascience and as Senior Vice President of Finance and Administration at BIND Therapeutics.
Chris obtained his MBA from Boston College and B.S. in Accounting from Syracuse University. Chris is a certified public accountant and started his career at PricewaterhouseCoopers.